Physician profile
Hans Liu
NPI 1568488625
$28,785.99
in general payments reported to CMS, 2019-2025
16 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $125 · 2021: $5,844 · 2022: $3,347 · 2023: $125 · 2024: $3,431 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,100 · Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,100.00 |
| Food and Beverage | $770.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo Company LTD | $20,609.23 | 2019-2024 | |
| Shionogi INC | $6,024.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $330.53 | 2021-2024 | Fasenra |
| Janssen Scientific Affairs, LLC | $237.76 | 2019-2020 | |
| Optinose US, INC. | $234.87 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.26 | 2022 | |
| Amarin Pharma, INC. | $126.31 | 2019 | |
| Insmed, INC. | $125.17 | 2022 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Aimmune Therapeutics, INC. | $124.98 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $119.78 | 2019 | |
| Abbvie INC. | $115.89 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.55 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.